REFERENCES
- Bikson, M., P. Grossman, C. Thomas, et al. 2016. Safety of transcranial direct current stimulation: Evidence-based update 2016. Brain Stimulation 9(5): 641–61. doi: 10.1016/j.brs.2016.06.004.
- Darrow, J. J. 2014. Crowdsourcing clinical trials. Minnesota Law Review 98:805–67.
- Eisenberg, R. S. 2007. The role of the FDA in innovation policy. Michigan Telecommunications and Technology Law Review 13:345–88.
- Food and Drug Administration. 2016. Draft guidance: Use of real-world evidence to support regulatory decision-making for medical devices. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm513027.pdf (accessed December 7, 2016).
- Maslen H., T. Douglas, R.C. Kadosh, N. Levy, and J. Savulescu. 2014. The regulation of cognitive enhancement devices: Extending the medical model. Journal of Law and the Biosciences 1(1): 68–93. doi:10.1093/jlb/lst003.
- Wexler, A. 2015. A pragmatic analysis of the regulation of consumer transcranial direct current stimulation (tDCS) devices in the United States. Journal of Law and the Biosciences 2(3): 669–96. doi:10.1093/jlb/lsv039.
- Wexler, A., and R. Hamilton. 2017. Crowdsourced tDCS research: Feasible or fanciful? AJOB Neuroscience 8(1): 50–53.
- Zettler, P. J. 2016. What lies ahead for FDA regulation of tDCS products? Journal of Law and the Biosciences 3(2): 318–23. doi:10.1093/jlb/lsw024.